GlassScriptPhysician profile
Mithila Vullaganti
NPI 1174758130
$2,000.71
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $129 · 2021: $945.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,065.32 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $418.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $189.16 | 2019 | |
| Allergan, INC. | $84.70 | 2019 | |
| Pfizer INC. | $39.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $39.44 | 2019-2020 | |
| Grifols USA, LLC | $27.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.52 | 2019 | |
| Amgen INC. | $21.80 | 2019 | |
| Boston Scientific Corporation | $20.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.38 | 2019 | |
| Ge Healthcare | $19.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.25 | 2019 | |
| Chiesi USA, INC. | $13.39 | 2020 |
Research and ownership
$1,435.48 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mithila Vullaganti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.